Related Experiment Video
Updated: Feb 16, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
Published on: August 7, 2017
Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura
Joan D Beckman1, Marian A Rollins-Raval2, Jay S Raval2
1Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC.
Abstract:
The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.
Related Concept Videos
Cell-mediated Immune Responses
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
What is the Immune System?
Humoral Immune Responses
Receptor-mediated Endocytosis
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...

